A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Small, Eric Jay
Lance, Raymond S.
Redfern, Charles H.
Millard, Frederick E.
Gardner, Thomas A.
Karsh, Lawrence Ivan
Dawson, Nancy Ann
McCoy, Candice
Stubbs, Andrew
DeVries, Todd
dela Rosa, Corazon P.
Sheikh, Nadeem A.
Shore, Neal D.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[3] Sharp Clin Oncol Res, San Diego, CA USA
[4] Moores UCSD Canc Ctr, San Diego, CA USA
[5] Urol Indiana Univ Hlth, Indianapolis, IN USA
[6] Urol Ctr Colorado, Denver, CO USA
[7] Georgetown Univ Med Ctr, Washington, DC USA
[8] Dendreon Corp, Seattle, WA USA
[9] Carolina Urol Res Ctr, Myrtle Beach, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5047
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC)
    Small, Eric Jay
    Lance, Raymond
    Gardner, Thomas A.
    Karsh, Lawrence Ivan
    Stubbs, Andrew
    McCoy, Candice
    DeVries, Todd
    Redfern, Charles H.
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [2] A Phase 2 trial of sipuleucel-T in combination with concurrent or sequential abiraterone acetate (AA) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Small, E.
    Lance, R.
    Gardner, T. A.
    Karsh, L. I.
    Stubbs, A.
    McCoy, C.
    DeVries, T.
    Redfern, C. H.
    Shore, N. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S682 - S683
  • [3] A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
    Small, Eric J.
    Lance, Raymond S.
    Gardner, Thomas A.
    Karsh, Lawrence I.
    Fong, Lawrence
    Mccoy, Candice
    DeVries, Todd
    Sheikh, Nadeem A.
    Thakurta, Debraj Guha
    Chang, Nancy
    Redfern, Charles H.
    Shore, Neal D.
    CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3862 - 3869
  • [4] Phase II Trial of Sipuleucel-T and Stereotactic Ablative Radiation therapy (SAbR) for Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Dohopolski, M.
    Watumull, L.
    Mathews, D.
    Gao, A.
    Garant, A.
    Choy, H.
    Ahn, C.
    Timmerman, R. D.
    Courtney, K.
    Hannan, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E879 - E879
  • [5] Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC).
    Small, Eric Jay
    Fong, Lawrence
    Quinn, David I.
    Drake, Charles G.
    Campogan, Dwayne
    Tuyen Vu
    Sheikh, Nadeem Anwar
    Chang, Nancy N.
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] A phase II randomized, open label study of sipuleucel-T versus sipuleucel-T and tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC)
    Pill, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer
    Hannan, Raquibul
    Dohopolski, Michael J.
    Pop, Laurentiu M.
    Mannala, Samantha
    Watumull, Lori
    Mathews, Dana
    Gao, Ang
    Garant, Aurelie
    Arriaga, Yull E.
    Bowman, Isaac
    Chung, Jin-Sung
    Wang, Jing
    Ariizumi, Kiyoshi
    Ahn, Chul
    Timmerman, Robert
    Courtney, Kevin
    BIOMEDICINES, 2022, 10 (06)
  • [8] OPENACT: PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)
    Corman, J.
    Dawson, N.
    Hall, S.
    Nabhan, C.
    Ferrari, A.
    Armstrong, A. J.
    Murdock, M. I.
    Stewart, F.
    Sheikh, N.
    Petrylak, D. P.
    ANNALS OF ONCOLOGY, 2012, 23 : 311 - 311
  • [9] A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer
    George, Daniel J.
    Halabi, Susan
    Heath, Elisabeth I.
    Sartor, A. Oliver
    Sonpavde, Guru P.
    Das, Devika
    Bitting, Rhonda L.
    Berry, William
    Healy, Patrick
    Anand, Monika
    Winters, Carol
    Riggan, Colleen
    Kephart, Julie
    Wilder, Rhonda
    Shobe, Kellie
    Rasmussen, Julia
    Milowsky, Matthew I.
    Fleming, Mark T.
    Bearden, James
    Goodman, Michael
    Zhang, Tian
    Harrison, Michael R.
    McNamara, Megan
    Zhang, Dadong
    LaCroix, Bonnie L.
    Kittles, Rick A.
    Patierno, Brendon M.
    Sibley, Alexander B.
    Patierno, Steven R.
    Owzar, Kouros
    Hyslop, Terry
    Freedman, Jennifer A.
    Armstrong, Andrew J.
    CANCER, 2021, 127 (16) : 2954 - 2965
  • [10] Dynamic changes in biomarkers for immune response to sipuleucel-t (SipT) for metastatic castrate-resistant prostate cancer (mCRPC).
    Hepgur, Mehmet Faith
    Dorff, Tanya B.
    Cai, Jie
    Reed, Mary
    Chan, Betty
    Quinn, David I.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345